Lilly's Cymbalta Label Adds Postmarketing Data On Hepatotoxicity
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling for Lilly's Cymbalta extends hepatotoxicity Precaution based on postmarketing reports.
You may also be interested in...
Duloxetine Drug Interactions Are Issue For Yentreve, But Not For Cymbalta
FDA’s neuropharm and urology review divisions hold differing opinions on duloxetine drug interactions, Cymbalta review documents indicate. Due to potential QT risk, urology division delays Yentreve approval for stress urinary incontinence; neuropharm division believes potential QT effect can be considered post-approval.
Cymbalta Approved; Lilly Antidepressant Will Be Available By Late August
Cymbalta (duloxetine) clears FDA for major depressive disorder after a lengthy review. It will be priced comparably to other antidepressants, including Wyeth's Effexor XR (venlafaxine), the other marketed selective serotonin/norepinephrine reuptake inhibitor.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.